1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Asia Pacific Cancer Targeted Therapy Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Asia Pacific Cancer Targeted Therapy Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Asia Pacific Cancer Targeted Therapy Market Regional Analysis
6.2 Asia Pacific Cancer Targeted Therapy Market Revenue 2021-2031 (US$ Million)
6.3 Asia Pacific Cancer Targeted Therapy Market Forecast Analysis
7. Asia Pacific Cancer Targeted Therapy Market Analysis – by Therapy Type
7.1 Monoclonal Antibodies
- 7.1.1 Overview
- 7.1.2 Monoclonal Antibodies: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Tyrosine Kinase Inhibitors
- 7.2.1 Overview
- 7.2.2 Tyrosine Kinase Inhibitors: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Immune Checkpoint Inhibitors
- 7.3.1 Overview
- 7.3.2 Immune Checkpoint Inhibitors: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Cancer Vaccines
- 7.4.1 Overview
- 7.4.2 Cancer Vaccines: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Gene Therapy
- 7.5.1 Overview
- 7.5.2 Gene Therapy: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Other Therapy Types
- 7.6.1 Overview
- 7.6.2 Other Therapy Types: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8. Asia Pacific Cancer Targeted Therapy Market Analysis – by Indication
8.1 Blood Cancer
- 8.1.1 Overview
- 8.1.2 Blood Cancer: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Lung Cancer
- 8.2.1 Overview
- 8.2.2 Lung Cancer: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Breast Cancer
- 8.3.1 Overview
- 8.3.2 Breast Cancer: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Colorectum Cancer
- 8.4.1 Overview
- 8.4.2 Colorectum Cancer: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Prostate Cancer
- 8.5.1 Overview
- 8.5.2 Prostate Cancer: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Stomach Cancer
- 8.6.1 Overview
- 8.6.2 Stomach Cancer: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.7 Cervical Cancer
- 8.7.1 Overview
- 8.7.2 Cervical Cancer: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.8 Liver and Intrahepatic Bile Duct Cancer
- 8.8.1 Overview
- 8.8.2 Liver and Intrahepatic Bile Duct Cancer: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.9 Thyroid Cancer
- 8.9.1 Overview
- 8.9.2 Thyroid Cancer: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.10 Other Indications
- 8.10.1 Overview
- 8.10.2 Other Indications: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9. Asia Pacific Cancer Targeted Therapy Market Analysis – by End User
9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Online Stores
- 9.3.1 Overview
- 9.3.2 Online Stores: Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
10. Asia Pacific Cancer Targeted Therapy Market – Asia-Pacific Analysis
10.1 Overview
10.2 Asia-Pacific
- 10.2.1 Asia Pacific Cancer Targeted Therapy Market Breakdown, by Key
Country, 2025 and 2031 (%)
- 10.2.1.1 Asia Pacific Cancer Targeted Therapy Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 Australia:
Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.1.1 Australia: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.1.2 Australia: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.1.3 Australia: Asia Pacific Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.2 China:
Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.2.1 China: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.2.2 China: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.2.3 China: Asia Pacific Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.3 India:
Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.3.1 India: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.3.2 India: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.3.3 India: Asia Pacific Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.4 Japan:
Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.4.1 Japan: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.4.2 Japan: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.4.3 Japan: Asia Pacific Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.5 South Korea:
Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.5.1 South Korea: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.5.2 South Korea: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.5.3 South Korea: Asia Pacific Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.6 Indonesia:
Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.6.1 Indonesia: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.6.2 Indonesia: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.6.3 Indonesia: Asia Pacific Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.7 Malaysia:
Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.7.1 Malaysia: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.7.2 Malaysia: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.7.3 Malaysia: Asia Pacific Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.8 Philippines:
Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.8.1 Philippines: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.8.2 Philippines: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.8.3 Philippines: Asia Pacific Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.9 Singapore:
Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.9.1 Singapore: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.9.2 Singapore: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.9.3 Singapore: Asia Pacific Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.10 Thailand:
Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.10.1 Thailand: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.10.2 Thailand: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.10.3 Thailand: Asia Pacific Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.11 Vietnam:
Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.11.1 Vietnam: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.11.2 Vietnam: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.11.3 Vietnam: Asia Pacific Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.12 Bangladesh:
Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.12.1 Bangladesh: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.12.2 Bangladesh: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.12.3 Bangladesh: Asia Pacific Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.13 New Zealand:
Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.13.1 New Zealand: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.13.2 New Zealand: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.13.3 New Zealand: Asia Pacific Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.14 Taiwan:
Asia Pacific Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.14.1 Taiwan: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.14.2 Taiwan: Asia Pacific Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.14.3 Taiwan: Asia Pacific Cancer Targeted Therapy Market Breakdown, by End User
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Astellas Pharma Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Eli Lilly and Co
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Novartis AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Merck KGaA
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Johnson & Johnson
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 AstraZeneca
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Pfizer Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Bristol Myers Squibb
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 F. Hoffmann-La Roche Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 AbbVie
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations